A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2285-2295

  Jiang, Yiling ^a   Gauthier, Aline ^a   Postma, Maarten J ^b   Ribassin Majed, Laureen ^c   Largeron, Nathalie ^d   Bresse, Xavier ^d  

^a Amaris   (United Kingdom)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SANOFI PASTEUR   (France)

Author keywords

Cost effectiveness; Economic evaluation; Human papillomavirus; Males; Strategy; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; HEAD AND NECK CANCER; HETEROSEXUAL MALE; HUMAN; INNATE IMMUNITY; MEN WHO HAVE SEX WITH MEN; MOUTH CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PROTECTION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS TRANSMISSION; VULVA CANCER; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOLOGY; MALE; PAPILLOMAVIRUS INFECTIONS; STATISTICAL MODEL; UTILIZATION;

COST-BENEFIT ANALYSIS; HUMANS; MALE; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84887458997     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25754     Document Type: Review

References (75)

1. Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010; 118(Suppl):S12-7; PMID: 20494219; http://dx.doi.org/10.1016/j.ygyno.2010.04.004
2. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362-72; PMID: 15187189; http://dx.doi.org/10.1128/MMBR.68.2.362-372.2004 (Pubitemid 38756870)
3. Bonnez W, Reichman RC. Papillomaviruses. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone Elsevier, 2010: 2035-2049.
4. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al.; Gynecologic Cancer Advisory Group. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57: 7-28; PMID: 17237032; http://dx.doi.org/10.3322/ canjclin.57.1.7 (Pubitemid 46148088)
5. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 Suppl 3:S3-11-S3/25.
6. European Medicines Agency. Gardasil: EPAR - product information. 31 July 2012. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR Product-Information/human/000703/WC500021142.pdf, accessed 14 June 2013.
7. European Medicines Agency. Cervarix: summary of opinion (post-authorisation). 21 February 2013. Available at http://www.ema.europa.eu/ docs/en-GB/document-library/Summary-of-opinion/human/000721/WC500139202.pdf, accessed 14 June 2013.
8. Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, et al. An overview on the implementation of HPV vaccination in Europe. Hum Vaccin 2011; 7(Suppl): 128-35; PMID: 21245659; http://dx.doi.org/10.4161/hv.7.0.14575
9. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomavi-ruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1-636; PMID: 18354839
10. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124: 1626-36; PMID: 19115209; http://dx.doi.org/10.1002/ijc.24116
11. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26(Suppl 10):K17-28; PMID: 18847554; http://dx.doi.org/10.1016/j.vaccine.2008.06.021
12. Gillison M. HPV and its effect on head and neck cancer prognosis. Clin Adv Hematol Oncol 2010; 8: 680-2; PMID: 21317864
13. Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, Arduino P, Campisi G, et al. Human papillomavi-ruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 2011; 17(Suppl 1): 58-72; PMID: 21382139; http://dx.doi.org/10.1111/j.1601-0825.2011.01792.x
14. Goon PK, Stanley MA, Ebmeyer J, Steinsträsser L, Upile T, Jerjes W, et al. HPV & head and neck cancer: a descriptive update. Head Neck Oncol 2009; 1: 36; PMID: 19828033; http://dx.doi.org/10.1186/1758-3284-1-36
15. Hartwig S, Syrjänen S, Dominiak-Felden G, Brotons M, Castellsagué X. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012; 12: 30; PMID: 22260541; http://dx.doi.org/10.1186/1471- 2407-12-30
16. Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 2011; 129: 733-41; PMID: 20878955; http://dx.doi.org/10.1002/ijc. 25699
17. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-9; PMID: 20451455; http://dx.doi.org/10.1016/S1470-2045(10)70017-6
18. Hocking JS, Stein A, Conway EL, Regan D, Grulich A, Law M, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 2011; 104: 886-91; PMID: 21285981; http://dx.doi.org/10.1038/sj.bjc.6606091
19. Brewster DH, Bhatti LA. Increasing incidence of squa-mous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer 2006; 95: 87-90; PMID: 16721368; http://dx.doi.org/10.1038/sj.bjc.6603175 (Pubitemid 43980559)
20. Jin F, Stein AN, Conway EL, Regan DG, Law M, Brotherton JM, et al. Trends in anal cancer in Australia, 1982-2005. Vaccine 2011; 29: 2322-7; PMID: 21255682; http://dx.doi.org/10.1016/j.vac-cine.2011.01.015
21. Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer 2012; 130: 1168-73; PMID: 21469144; http://dx.doi.org/10.1002/ijc.26115
22. von Krogh G; von KG. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001; 11: 598-603, quiz 604; PMID: 11701422 (Pubitemid 33044469)
23. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24 Suppl 3:S3-35-S3/41.
24. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998; 9: 571-8; PMID: 9819106; http://dx.doi.org/10.1258/ 0956462981921143 (Pubitemid 28474812)
25. Woodhall S, Ramsey T, Cai C, Crouch S, Jit M, Birks Y, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008; 84: 161-6; PMID: 18339658; http://dx.doi.org/10.1136/sti.2007. 029512 (Pubitemid 351871484)
26. Bundesministerium für Gesundheit. Impfplan Österreich 2013. Evidenz-basierte Empfehlungen des Nationalen Impfgremiums. 2013. Available at http://bmg.gv.at/cms/home/attachments/3/3/6/CH1100/CMS1327680589121/ impfplan2013.pdf, accessed 14 June 2013.
27. Landesärztekammer S. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen. 1 January 2013. Available at http://www.slaek.de/de/03/36impfen/pdf/E1-2013- Druck.pdf, accessed 14 June 2013.
28. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60: 1705-8; PMID: 22189893
29. National Advisory Committee on Immunization. Update on human papillomavirus (HPV) vaccines. Can Commun Dis Rep 2012; 38: 1-62
30. Department of Health and Ageing. HPV vaccine extended to boys. 2012. Available at http://www. health.gov.au/internet/ministers/publishing.nsf/Conte nt/59C397F61CACF02FCA257A390000C65A/$Fi le/TP059.pdf, accessed 14 June 2013.
31. Department of Health and Ageing. Fact sheet. National Immunisation Program - HPV vaccination for boys. 2012. Available at http://www.health.gov.au/ internet/immunise/publishing.nsf/Content/1958E1814219368 8CA2575BD001C80CA/ $File/HPV-vaccination-for-boys-factsheet.pdf, accessed 14 June 2013.
32. Centers for Disease Control and Prevention. The VFC program: at a glance. 31 August 2012. Available at http://www.cdc.gov/vaccines/programs/vfc/about/ index.html, accessed 14 June 2013.
33. Prince Edward Island Department of Health and Wellness. HPV vaccine program expands to include boys. 18 April 2013. Available at http://www.gov.pe.ca/health/index.php3?number=news&dept=&newsnumb er=8937&lang=Econtent, accessed 14 June 2013.
34. Vorarlberg L. Verbesserung der Gesundheitsvorsorge für Jugendliche. HPV-Impfung wird deutlich billiger. 24 January 2013. Available at http://www.vorarlberg. at/doc/hpv-pku.doc, accessed 14 June 2013.
35. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papilloma-virus vaccine: a systematic review. Pharmacoeconomics 2009; 27: 127-47; PMID: 19254046; http://dx.doi.org/10.2165/ 00019053-200927020-00004
36. Seto K, Marra F, Raymakers A, Marra CA. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs 2012; 72: 715-43; PMID: 22413761; http://dx.doi.org/10.2165/11599470-000000000-00000
37. Garnett G P, Cousens S, Hallett TB, Steketee R, Walker N. Mathematical models in the evaluation of health programmes. Lancet 2011; 378: 515-25; PMID: 21481448; http://dx.doi.org/10.1016/S0140-6736(10)61505-X
38. Insinga R P, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007; 26: 128-39; PMID: 18055075; http://dx.doi.org/10.1016/j.vaccine.2007.10.056 (Pubitemid 350218187)
39. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007; 4: 165-75; PMID: 17931529; http://dx.doi.org/10.1071/SH07043 (Pubitemid 47339645)
40. Elbasha EH, Dasbach EJ, Insinga R P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41; PMID: 17370513; http://dx.doi.org/10.3201/eid1301.060438 (Pubitemid 46057835)
41. Zechmeister I, Blasio B F, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human pap-illomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009; 27: 5133-41; PMID: 19567244; http://dx.doi.org/10.1016/j.vac-cine.2009.06.039
42. Taira AV, Neukermans C P, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-23; PMID: 15550200; http://dx.doi.org/10.3201/eid1011.040222 (Pubitemid 39458555)
43. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010; 10: 845-52; PMID: 21051295; http://dx.doi.org/10.1016/S1473-3099(10)70219- X
44. XE.com. Universal currency converter. 19 September 2012. Available at http://www.xe.com, accessed 19 September 2012.
45. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28: 6858-67; PMID: 20713101; http://dx.doi.org/10.1016/j.vaccine.2010.08.030
46. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769; PMID: 18640957; http://dx.doi.org/10.1136/bmj.a769
47. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339:b3884; PMID: 19815582; http://dx.doi.org/10.1136/bmj. b3884
48. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010; 26: 183-91; PMID: 20392322; http://dx.doi.org/10.1017/S0266462310000085
49. Chesson HW, Ekwueme DU, Saraiya M, Dunne E F, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011; 29: 8443-50; PMID: 21816193; http://dx.doi.org/10.1016/j.vaccine.2011.07.096
50. Bonabeau E. Agent-based modeling: methods and techniques for simulating human systems. Proc Natl Acad Sci U S A 2002; 99(Suppl 3): 7280-7; PMID: 12011407; http://dx.doi.org/10.1073/pnas.082080899 (Pubitemid 34522724)
51. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26: 191-215; PMID: 18282015; http://dx.doi.org/10.2165/00019053-200826030-00004 (Pubitemid 351271379)
52. Regan DG, Philp DJ, Waters EK. Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective. Sex Health 2010; 7: 368-75; PMID: 20719229; http://dx.doi.org/10.1071/SH10006
53. Allal AS, Sprangers MA, Laurencet F, Reymond MA, Kurtz JM. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer 1999; 80: 1588-94; PMID: 10408404; http://dx.doi.org/10.1038/sj.bjc.6690567 (Pubitemid 29308641)
54. de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Long-term quality of life of patients with head and neck cancer. Laryngoscope 2000; 110: 98-106; PMID: 10646723; http://dx.doi.org/10.1097/00005537-200001000- 00018 (Pubitemid 30046653)
55. Jeffreys M, Rachet B, McDowell S, Habib AG, Lepage C, Coleman M P. Survival from rectal and anal cancers in England and Wales, 1986-2001. Eur J Cancer 2006; 42: 1434-40; PMID: 16600590; http://dx.doi.org/10.1016/j.ejca.2006. 01.019 (Pubitemid 44183847)
56. Maddineni SB, Lau MM, Sangar VK. Identifying the needs of penile cancer sufferers: a systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer. BMC Urol 2009; 9: 8; PMID: 19664235; http://dx.doi.org/10.1186/1471-2490-9-8
57. Pirotta M, Ung L, Stein A, Conway EL, Mast TC, Fairley CK, et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect 2009; 85: 508-13; PMID: 19703844; http://dx.doi.org/10.1136/sti.2009.037028
58. Bray F, Klint A, Gislum M, Hakulinen T, Engholm G, Tryggvadóttir L, et al. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003 followed up until the end of 2006. Acta Oncol 2010; 49: 644-54; PMID: 20151937; http://dx.doi.org/10.3109/02841860903575315
59. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-9; PMID: 20451455; http://dx.doi.org/10.1016/S1470-2045(10)70017-6
60. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-86; PMID: 21471563; http://dx.doi.org/10.1093/annonc/mdr015
61. Mortensen GL, Paaske PB. Patients perceive tonsil cancer as a strike at psycho-socially "vital organs". Dan Med J 2012; 59:A4504; PMID: 22951199
62. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB; ISPOR-SMDM Modeling Good Research Practices Task Force. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making 2012; 32: 733-43; PMID: 22990088; http://dx.doi.org/ 10.1177/0272989X12454579
63. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in European Union countries - an update. September 2012. Available at http://ecdc.europa.eu/en/publications/publica-tions/20120905-gui-hpv-vaccine- update.pdf, accessed 14 June 2013.
64. Department of Health and Ageing. Quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombi-nant vaccine, solution for injection, 0.5 mL, solution for injection pre-filled syringe single dose, Gardasil®. November 2011. Available at http://www.health.gov. au/internet/main/publishing.nsf/Content/ pbac-psd-quadrivalent-nov11, accessed 14 June 2013.
65. Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ 2010; 19: 43-55; PMID: 19206080
66. Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD. A framework for addressing structural uncertainty in decision models. Med Decis Making 2011; 31: 662-74; PMID: 21602487; http://dx.doi.org/10.1177/0272989X11406986
67. Strong M, Oakley JE, Chicott J. Managing structural uncertainty in health economic decision models: a discrepancy approach. J R Stat Soc Ser C Appl Stat 2012; 61: 25-45; http://dx.doi.org/10.1111/j.1467-9876.2011.01014.x
68. Baussano I, Garnett G, Segnan N, Ronco G, Vineis P. Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine 2011; 29: 1270-7; PMID: 21145375; http://dx.doi.org/10.1016/j.vac-cine.2010.11.082
69. Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 2010; 28: 5473-84; PMID: 20573580; http://dx.doi.org/10.1016/j.vaccine. 2010.05.056
70. Garattini L, van de Vooren K, Curto A. Pricing human papillomavirus vaccines: lessons from Italy. Pharmacoeconomics 2012; 30: 213-7; PMID: 22233523; http://dx.doi.org/10.2165/11596560-000000000-00000
71. Wallace LA, Young D, Brown A, Cameron JC, Ahmed S, Duff R, et al. Costs of running a universal adolescent hepatitis B vaccination programme. Vaccine 2005; 23: 5624-31; PMID: 16099079; http://dx.doi.org/10.1016/j.vaccine.2005.06. 034 (Pubitemid 41608612)
72. Myers ER, Green S, Lipkus I. 542 Patient preferences for health states related to HPV infection: visual analog scales vs time trade-off elicitation. Proceedings of 21st International Papillomavirus Conference.
73. Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, et al. Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy 2009; 93: 85-92; PMID: 19709773; http://dx.doi.org/10.1016/j.healthpol.2009.07.012
74. Bärnighausen T, Bloom DE, Cafiero E T, O'Brien JC. Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavi-rus. Clin Microbiol Infect 2012; 18(Suppl 5): 70-6; PMID: 22882176; http://dx.doi.org/10.1111/j.1469-0691.2012.03977.x
75. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine 2007; 25: 5945-57; PMID: 17629362; http://dx.doi.org/10.1016/j.vaccine.2007.04.070 (Pubitemid 47082460)